Immuno-oncology represents a form of cancer treatment that harnesses the power of the body's own immune system to potentially prevent, control, and eliminate cancer. The rapid progress of modern immunotherapeutics meets several clinical needs to a certain extent. However, there are still some limitations.
For instance, the proportion of cancer patients who may potentially benefit from and respond to PD-1/PD-L1 inhibitors is generally not more than 30%, and the occurrence of acquired drug resistance is relatively common. For cold tumors (such as tumors lacking T cell infiltration) or tumors with immunosuppressive tumor microenvironments (TME), the response rate of current immunotherapeutics is relatively low. Additionally, issues such as high therapy costs and inconvenient administration methods also exist.
To address these challenges, Baiyu is exploring new therapeutic modalities to potentially activate the immune microenvironment and counter multiple tumor escape mechanisms, aiming to overcome some of the limitations of current immunotherapy.